For Health Care Professionals Only.
Thank you for your interest. StrandDx-ASD diagnostic aid is based on novel molecular biomarkers established using Linus Biotechnology’s proprietary exposome and biological response sequencing platform. The FDA has awarded breakthrough designation to StrandDx-ASD, and we are working closely with the FDA for full approval in the United States. Please complete this form to sign up for updates on the development and availability of StrandDx-ASD diagnostic aid.